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Abstract
Background: Adverse consequences of medical interventions are a source of concern, but clinical trials may lack
power to detect elevated rates of such events, while observational studies have inherent limitations. Meta-analysis
allows the combination of individual studies, which can increase power and provide stronger evidence relating to
adverse events. However, meta-analysis of adverse events has associated methodological challenges. The aim of this
study was to systematically identify and review the methodology used in meta-analyses where a primary outcome is
an adverse or unintended event, following a therapeutic intervention.
Methods: Using a collection of reviews identiﬁed previously, 166 references including a meta-analysis were selected
for review. At least one of the primary outcomes in each review was an adverse or unintended event. The nature of
the intervention, source of funding, number of individual meta-analyses performed, number of primary studies
included in the review, and use of meta-analytic methods were all recorded. Speciﬁc areas of interest relating to the
methods used included the choice of outcome metric, methods of dealing with sparse events, heterogeneity,
publication bias and use of individual patient data.
Results: The 166 included reviews were published between 1994 and 2006. Interventions included drugs and
surgery among other interventions. Many of the references being reviewed included multiple meta-analyses with
44.6% (74/166) including more than ten. Randomised trials only were included in 42.2% of meta-analyses (70/166),
observational studies only in 33.7% (56/166) and a mix of observational studies and trials in 15.7% (26/166). Sparse
data, in the form of zero events in one or both arms where the outcome was a count of events, was found in 64
reviews of two-arm studies, of which 41 (64.1%) had zero events in both arms.
Conclusions: Meta-analyses of adverse events data are common and useful in terms of increasing the power to
detect an association with an intervention, especially when the events are infrequent. However, with regard to
existing meta-analyses, a wide variety of diﬀerent methods have been employed, often with no evident rationale for
using a particular approach. More speciﬁcally, the approach to dealing with zero events varies, and guidelines on this
issue would be desirable.
Background
There is increasing concern regarding adverse outcomes
of therapeutic interventions, which may be addressed by
bringing together evidence frommultiple sources [1]. The
Cochrane Collaboration, in its remit to undertake sys-
tematic reviews, has considered adverse events as an area
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worthy of consideration as a deﬁned clinical area that
requires speciﬁc methodology [2], but the emphasis was
placed on the non-statistical elements, such as choice
of outcomes, study types and search strategies. The use
of quantitative evidence synthesis methods with adverse
events speciﬁcally in mind has been considered some
time ago [3], but there is little empirical information col-
lated on meta-analytic approaches within adverse event
meta-analyses.
A recent review of systematic reviews of adverse events
in response to drug interventions included 43 review
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articles published in 2006 [4]. However, the statistical
methods could only be reviewed in the 24 of these that
included a meta-analysis. This review also considered the
search strategies used in the systematic reviews of adverse
events, and this ﬁeld has been better documented since it
is the focus of several further studies [5-9].
The aim of this current systematic review is to inves-
tigate the meta-analytic methodology used where the
primary outcome of the meta-analysis was an adverse
or unintended event, with the aims of identifying which
methods have been used and the challenges faced by
authors. A wide range of therapeutic interventions are
considered, including drugs, surgical procedures, devices,
vaccinations, dietary interventions, anaesthetics and pub-
lic health programmes. It is hoped that this review will
assist in development and standardisation of methods
in future and we discuss the areas of priority for fur-
ther research to facilitate the development of guide-
lines to support meta-analysis of adverse and unintended
outcomes data.
Methods
The dataset of meta-analyses for this current survey was
identiﬁed using a database of systematic reviews collected
previously [7]. The aim of this previous study was to
develop and evaluate search strategies for the retrieval of
systematic reviews, which may or may not include a meta-
analysis, where the primary outcome was an adverse event
(or unintended but positive event) resulting from a clinical
intervention. The databases searched (both electronically
and by hand) in the previous study were the Database of
Abstracts of Reviews of Eﬀects (DARE) and the Cochrane
Database of Systematic Reviews (CDSR). Details of the
search strategy have been described [7].
These search strategies yielded a total of 257 systematic
reviews (246 from DARE plus 11 Cochrane reviews),
published between 1994 and 2006. The initial searches
were updated, yielding a further 20 systematic reviews on
adverse events [9], producing 277 in total.
From the systematic reviews above, references were
selected for inclusion in the current review according to
the following criteria:
1. some form of quantitative synthesis (or test for
heterogeneity with intention to perform a
quantitative synthesis if appropriate) must be
performed using more than one observed estimate of
eﬀect;
2. the study group of interest must have received some
form of clinical intervention with intended or
potential therapeutic eﬀect; and
3. the full study report must be available in English.
A quantitative data synthesis may take the form of a
pooled estimate, a conﬁdence interval, quoting a p-value
only, or performing a meta-regression. Studies entailing
only qualitative evidence synthesis, although having an
essential role to play in the assessment of adverse events,
were not included in this review, which is exclusively
aimed at statistical synthesis methods. Meta-analyses of
unintended or adverse reactions associated with non-
interventional activities, for example recreational drug
use, were excluded.
Included reviews were evaluated on multiple aspects.
These included type of intervention, number of primary
studies incorporated, number of individual meta-analyses
performed and source of funding (when determin-
ing sponsorship, any form of commercial funding was
counted as such, even if other sources of funding were also
present; similarly, government sponsorship took prece-
dence over academic). The statistical aspects included
general meta-analysis methods and how speciﬁc chal-
lenges were addressed. These included (i) dealing with
sparse data (a count of zero events in one arm of study or
zero events across the whole study); (ii) statistical hetero-
geneity; (iii) dissemination biases (primarily publication
bias); (iv) variable quality of primary studies; and (v) use
of individual patient data (IPD).
Results
Description of included reviews
In total, 166 reviews including a meta-analysis fulﬁlled
all criteria and were included in this systematic review
[10-175]. Of these, 14 were Cochrane reviews, the others
were published in a wide variety of medical journals or
were reviews published by health agencies. Table 1 shows
a breakdown of number of included reviews by publica-
tion year and type.
Table 1 Number of included reviews by year of publication
Year of No. included Published Cochrane Other publication
publication reviews (%)1 in journal review type
1994 4 (2.4) 4 0 0
1995 8 (4.8) 8 0 0
1996 9 (5.4) 9 0 0
1997 15 (9.0) 15 0 0
1998 16 (9.6) 16 0 0
1999 19 (11.4) 18 1 0
2000 11 (6.6) 11 0 0
2001 22 (13.3) 22 0 0
2002 21 (12.7) 17 2 2
2003 22 (13.3) 20 2 0
2004 13 (7.8) 10 3 0
2005 4 (2.4) 0 4 0
2006 2 (1.2) 0 2 0
1Out of 166 included reviews.
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The interventions being evaluated for adverse events
were similarly diverse; by far the largest category was drug
interventions (69.9%, 116/166). The next largest category
was surgical interventions (8.4%, 14/166). Other types
of intervention, such as forms of anaesthesia, devices,
and diagnostic procedures, each accounted for fewer
than 5% of the included reviews. Multiple interventions
(often multiple therapies for cancer being assessed simul-
taneously) were considered by 5.4% (9/166) of included
reviews.
With regard to sponsorship, the largest number of
included reviews were academically sponsored (45.8%;
76/166). Commercial sponsorship accounted for 16.3%
(27/166), while 30.1% (50/166) were sponsored by some
form of government body. Other sponsorship sources pro-
vided funding for 7.2% (12/166), while funding source was
not stated for one included review.
Of the 166 included reviews, all except one included
some overall combined estimate. The one included review
that did not report a combined estimate included a meta-
regression for dose–response with no overall pooled esti-
mate of eﬀect size.
The number of meta-analyses performed in each
included review was also very variable. In many cases
a large number of meta-analyses were performed, with
44.6% (74/166) of studies having more than 10 meta-
analyses. By comparison, 19.3% (32/166) of studies had
6 −10 meta-analyses, 29.5% (49/166) had 2–5 meta-
analyses, 6.0% (10/166) had only one meta-analysis while
0.60% (1/166) had none (meta-regression only).
The number of primary cohorts (contributing a data
observation to themeta-analysis) is shown in Table 2. This
Table 2 Maximum andminimum numbers of contributing
estimates for meta-analyses in the same included review
Maximum no. Minimum no. No. included
data observations1 data observations reviews (%)2
2−5 2−5 17 (10.4)
6−10 2−5 34 (20.7)
6−10 6−10 6 (3.7)
11−20 2−5 50 (30.5)
11−20 6−10 5 (3.0)
11−20 11−20 4 (2.4)
>20 2−5 29 (17.7)
>20 6−10 12 (7.3)
>20 11−20 3 (1.8)
>20 >20 4 (2.4)
1A single primary study may contribute more than one data observation, hence
number of data observations may not be the same as number of primary studies.
2Out of 164 included reviews with at least one pooled estimate and number of
data observations stated.
table indicates that many included reviews performed
multiple meta-analyses with varying numbers of data
observations derived from primary studies, possibly
reﬂecting multiple outcomes or subgroup analyses.
Statistical methodology aspects
Table 3 sets out the number of included reviews that cover
heterogeneity, quality and dissemination bias, by year of
publication, to examine any changes over time.
Outcomemeasures
Table 4 shows the proportions of included reviews using
diﬀerent eﬀect measures. This is important because the
choice of outcome measure may in itself inﬂuence the
meta-analysis method and results.
In Table 4 the option ‘More than one’ was only selected
in the eventuality that there was no obvious primary out-
come metric, but instead at least two outcome metrics
that appeared to receive approximately equal importance
in the meta-analyses. Otherwise, the primary outcome
measure was recorded even if there were other outcome
metrics used in secondary analyses such as sensitivity
analyses.
Many of the outcomes being reported in the primary
studies were binary, thus lending themselves to analysis
by odds ratio or relative risk, as seen in Table 4. A dif-
ference scale (for example risk diﬀerence), as opposed to
a ratio scale, was chosen only infrequently. Only 9.6%
of studies presented more than one outcome measure.
This indicated that either more than one clinical outcome
was being investigated, requiring a diﬀerent outcomemet-
ric, or that the authors had presented analyses for the
same clinical outcome on equal terms for diﬀerent out-
comemetrics, possibly intended as a comparison between
the two.
Meta-analysis methodology
Another major area of interest was the methodology
used for the meta-analysis itself. Table 5 sets out the
meta-analysis method used to combine studies along with
numbers and percentages.
As seen in Table 5, ﬁxed and random eﬀect(s) models
were used with roughly equal frequency. The term ‘stan-
dard ﬁxed eﬀect’ was used when the authors chose an
accepted ﬁxed eﬀect model, such as the Mantel–Haenszel
model [176], the inverse variance model or the Peto
model [177]. Also, if the authors used any referenced ﬁxed
eﬀect model this was recorded as ‘standard ﬁxed eﬀect’. In
several cases the authors had used a method of combining
data that would be considered as a ‘ﬁxed eﬀect’ model, but
appeared to have either used a mean or weighted mean,
or a logistic regression method, or had devised their own
method for combining data, for example based on sam-
ple size of the studies. Such methods were considered
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Table 3 Percentages of included reviews by year including assessment of heterogeneity, quality and dissemination bias
Total no. included Heterogeneity Quality Dissemination bias
Year reviews (no. (%)) (no. (%)) (no. (%))
1994 4 2 (50) 1 (25) 1 (25)
1995 8 7 (88) 1 (13) 4 (50)
1996 9 8 (89) 1 (11) 6 (67)
1997 15 12 (80) 8 (53) 5 (33)
1998 16 14 (88) 3 (19) 10 (63)
1999 19 18 (95) 8 (42) 12 (63)
2000 11 9 (82) 4 (36) 4 (36)
2001 22 19 (86) 8 (36) 15 (68)
2002 21 16 (76) 13 (62) 8 (38)
2003 22 16 (73) 10 (45) 15 (68)
2004 13 11 (85) 7 (54) 5 (38)
2005 4 4 (100) 4 (100) 3 (75)
2006 2 2 (100) 2 (100) 1 (50)
non-standard and were recorded as ‘other ﬁxed eﬀect’.
Interestingly, all the random eﬀects models were
referenced standard models (referred to as standard ran-
dom eﬀects in Table 5, such as the DerSimonian & Laird
model [178]).
A record of ‘Multiple analysis methods’ was only
selected when there was more than one method used on
an equal basis. If there was an obvious primary method
Table 4 Measure of eﬀect
Measure of No. included Percent included
eﬀect reviews reviews1
Comparative measures (between interventions)
Odds ratio 55 33.1
Relative risk 51 30.7
Risk diﬀerence 8 4.8
Mean diﬀerence 6 3.6
Standardised mean diﬀerence 7 4.2
Percent diﬀerence 2 1.2
Non-comparative measures
Correlation 2 1.2
Probability (or percent) 13 7.8
Mean diﬀerence 2 1.2
Percent diﬀerence 3 1.8
Multiple measures
More than one 16 9.6
Other measures
Other 1 0.6
1Out of 166 included reviews.
with additional supplementary methods the primary me-
thod was chosen.
The one meta-analysis reference referred to as ‘Other’
used a novel approach developed by the authors of ‘sum-
mary ranking’ involving assigning a score to the rank order
of toxicity in individual primary studies, and then combin-
ing the scores to provide an overall rank order for toxicity.
One study included a meta-regression as the only quanti-
tative analysis, whilst another study performed a test for
heterogeneity but did not produce any pooled estimates.
In only three cases was there insuﬃcient detail regarding
the methodology to allow the type of analysis to be deter-
mined. In ﬁve of the reviewed studies the meta-analysis
method was not stated.
Table 5 Meta-analysis methods
Meta-analysis No. included Percent included
method reviews reviews1
Standard ﬁxed eﬀect2 54 32.5
Other ﬁxed eﬀect2 9 5.4
Standard random eﬀects2 50 30.1
Marginal analysis 3 1.8
Bayesian methods 6 3.6
Multiple analysis methods 33 19.9
Other 1 0.6
Not stated 5 3.0
Meta-regression only 1 0.6
Heterogeneity test only 1 0.6
Unclear 3 1.8
1Out of 166 included reviews.
2See text for deﬁnition.
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A Bayesian approach was used by six included reviews,
but in some cases the Bayesian model used in the
meta-analysis was not fully described. Semi-Bayesian
methods, incorporating a Bayesian use of a prior distri-
bution on the rate of the adverse event alongside stan-
dard frequentist methods, were also used in one included
review. This meta-analysis also experimented with the
use of diﬀerent prior distributions for the parameters.
However, none of these studies presented graphical repre-
sentations of the probability densities for the parameters.
Not taking into account the speciﬁcmethod of themeta-
analysis, 74/166 (44.6%) used a ﬁxed eﬀect model. This
included one review that stated that a random eﬀects
model was used, but in the absence of heterogeneity the
presented results were ﬁxed eﬀect. (The novel method
using rank summaries was also a ﬁxed eﬀect approach.)
Three included reviews where the methodology was not
described in suﬃcient detail to be classed as a standard or
other ﬁxed eﬀect model, were, however, able to be classed
as ﬁxed eﬀect in their approach.
A random eﬀects model was used by 53/166 (31.9%)
included reviews, including four of the reviews that used
Bayesian methods. Hence, it is apparent that ﬁxed and
random eﬀect(s) models were used with roughly equal
frequency.
Both ﬁxed and random eﬀect(s) models were used in
28/166 (16.9%) included reviews, including one that used
Bayesian methods. In the other cases it was not applicable
(5/166; 3.0%), or not stated (5/166; 3.0%). It was unclear
whether ﬁxed or random eﬀect(s) had been used in one
included review only.
The reasons why the authors chose a particular model
were recorded in 69/166 (41.6%) included reviews.
Reasons based upon heterogeneity (or between-study
variation) were the most commonly cited (46/69; 66.7%).
Increased conservatism (of a random eﬀects model) was
also frequently mentioned; 7/69 (10.1%) reviews alluded
to this.
Other reasons cited in support for a particular meta-
analysis method included diﬀerences in primary study
types, and so that larger studies would contribute more
to the meta-analysis. Arriving at similar results from both
ﬁxed and random eﬀect(s) models was also used to justify
the chosen approach. Only one included review oﬀered
multiple explanations, while nine oﬀered an explanation
not mentioned above.
Type of primary study and approaches to inclusion
The types of primary study encountered by included
reviews are set out in Table 6. The most frequent study
type was some form of trial, the sole study type for
46.4% (77/166) of included reviews. Trials were clearly
deﬁned as being randomised and/or controlled in some
included reviews. The 26 reviews (26/166, 15.7%) that
Table 6 Primary study types incorporated within included
reviews
Study types No. included reviews % included reviews1
Randomised trials 70 42.2
Other trials2 7 4.2
Observational studies 56 33.7
Mixed (trials and
observational studies) 26 15.7
Not stated 7 4.2
1Out of 166 included reviews.
2May include randomised trials but not speciﬁcally stated as such.
included both trials and observational studies demon-
strated a wide variety of approaches taken to this situation,
often reﬂecting the number of each diﬀerent type of study.
Some included reviews made no attempt to diﬀerentiate
by study design. In some included reviews there was only
one trial, all other studies were observational, and in one
of these reviews, the trial was excluded, although its inclu-
sion did not alter the results. In another instance with only
one trial, it was excluded from all meta-analyses, only the
observational studies (of diﬀerent designs) being included.
In one included review the sole trial was excluded due to
no events being observed in one group of the trial; simi-
larly, in another review with only one trial, this study was
excluded due to the small number of outcome events.
The most common approach to mixed study types was
to perform a sensitivity analysis by analysing all pri-
mary studies together and then dividing the studies by
some element of study design. For example, one included
review combined all studies together and then case–
control studies were analysed separately, and cohort stud-
ies were combined with trials. Some variation on this
theme was followed by several other included reviews.
Another approach was to avoid combination of estimates
across study designs altogether, by combining results from
studies with similar designs.
Graphical representations of data
Graphical representations of data were used in the major-
ity of included reviews. Forest plots were the only graph
used in 53.0% (88/166) of reviews, while meta-regression
plots were the only plot in 1.8% (3/166). Both forest plots
and meta-regression plots appeared in 1.8% (3/166) of
included reviews. Other plots were used in 18.1% (30/166)
of included reviews, usually a plot of the individual stud-
ies but lacking a pooled estimate. Only 25.3% (42/166) of
included reviews produced no graphical representations
of their results.
Publication Bias
Publication bias was considered in 89/166 (53.6%) of
included reviews. This issue may not have been speciﬁ-
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cally described in terms of publication bias. For example,
some included reviews performed searches for unpub-
lished primary studies, indicating that publication bias
was within the awareness of the authors when performing
a meta-analysis even if it was not taken any further than
searching for such primary studies.
Publication bias was discussed but not formally eval-
uated in 44/166 (26.5%) included reviews. A quantita-
tive analysis was performed by 31/166 (18.7%) included
reviews. A sensitivity analysis by publication status was
the preferred method of investigating publication bias for
one review.
Of 31 included reviews with some form of quantitative
analysis, 12 (38.7%) used a test with a p-value. The other
19/31 (61.3%) used an alternative method not resulting
in a p-value. The most commonly used tests were Egger’s
test [179] and Begg’s test [180]. Kendall’s tau test was
mentioned by three included reviews.
The trim and ﬁll method [181] was used to adjust for
publication or selection bias in two included reviews.
These were the only reviews that attempted to adjust for
these types of bias. Graphical methods (funnel plots) were
used to investigate for publication bias (or selection bias)
in 29/166 reviews (17.5%).
The vast majority of included reviews used only pub-
lished primary studies (129/166; 77.7%). Published pri-
mary studies with unpublished data (obtained through
contact with the authors), were used in 20/166 (12.0%)
included reviews. Both published and unpublished pri-
mary studies were used in 14/166 (8.4%) reviews. In the
other reviews the study source(s) was either unclear or not
stated. In several reviews where published primary stud-
ies only were included, it was made clear that unpublished
data had been sought.
Heterogeneity
Heterogeneity was considered in somemanner by 138/166
included reviews (83.1%), whether by a quantitative or
qualitative assessment, or by a subgroup analysis or meta-
regression. Meta-regression was included in nine reviews
that had no other assessment of heterogeneity, whilst one
review discussed issues regarding combination of primary
studies with diﬀerent criteria, but did not do a formal
qualitative or quantitative analysis of heterogeneity. Of
the remaining 128 included reviews, a quantitative assess-
ment was performed in 124 (124/166; 74.7%). A qualita-
tive assessment of heterogeneity (for example, inspection
of forest plots or noting heterogeneous results) was made
in 10/166 (6.0%) included reviews. Six included reviews
incorporated both quantitative and qualitative aspects of
heterogeneity assessment (6/166; 3.6%).
Considering quantitative analysis methods, 121/166
(72.9%) included reviews employed some form of statis-
tical test for heterogeneity, although with variation in the
chosen critical p-value for signiﬁcance. The chosen sig-
niﬁcance value was 0.05 for 28 reviews (23.1% of the 121
studies that performed a test), while 23/121 chose a more
liberal p-value of 0.1 (19.0%). Only one included review
chose 0.2 as the cut-oﬀ p-value. In many reviews the
actual p-value was quoted without reference to a partic-
ular threshold (51/121 reviews (42.1%) did this). In the
other reviews no p-value or signiﬁcance level was stated.
An estimate for heterogeneity was presented by 16/121
included reviews with a quantitative analysis (13.2%).
The most frequently-used estimate measure was the I2
statistic [182,183], which was used in 13 reviews. Alter-
native estimate measures included the between-studies
variance. One review used another estimate measure, the
R(I) statistic [184]. Only one included review used multi-
ple estimate measures; the estimates used included I2 and
the Q statistic [185].
Two ways to investigate the causes of heterogeneity are
subgroup analysis andmeta-regression. Subgroup analysis
was performed in 27/128 (21.1%) reviews that included an
analysis of heterogeneity, and in two reviews that did not
formally assess heterogeneity. Meta-regression was used
in 27 included reviews in total (27/166; 16.3%). In nine
of these reviews, no formal assessment of heterogeneity
had been performed. The covariates used in the meta-
regression analyses were often very speciﬁc to the nature
of the intervention or outcome being considered. A quali-
tative investigation of sources of heterogeneity was carried
out in 17/138 reviews that considered heterogeneity in
some way (12.3%).
Individual patient data
Very little use was made of IPD in the reviewed meta-
analyses. Only two included reviews of the total 166
(1.2%) included IPD. Of these two, all primary studies
included had IPD available (so there was no requirement
to combine IPD and summary data). Both reviews used
a one-stage method for the meta-analysis. In one review
the meta-analysis was stratiﬁed by trial and other factors
including centre within study for multicentre studies and
age divisions. In the other review it was not stated whether
the meta-analysis was stratiﬁed or not.
Sparse data
The issue of sparse data, whereby statistical methods were
required to allow the inclusion of primary studies where
the outcome was a count of zero, or a percent of zero,
occurred in 65/166 included reviews (39.2%), one of which
was a meta-analysis of single-arm studies only. Speciﬁc
statistical methods may be required to allow incorpo-
ration of such a primary study into an overall pooled
estimate or for calculation of conﬁdence intervals. For 62
of the 65 reviews in which sparse data occurred, the out-
come was on a comparative scale (an odds ratio, relative
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risk, or risk diﬀerence); this methodological area is the
focus of this review. The primary issues are (i) outcome
measures used by meta-analyses with zero events; (ii)
use of continuity corrections; (iii) methods for inclusion
of primary studies with zero events that do not involve
continuity corrections; and (iv) incorporation of primary
studies with zero events in both arms.
Of the 64 included reviews that considered the issue of
sparse data in two-arm studies, 41 (64.1%) had datasets
involving double-zero (zero events in both arms) primary
studies. In the remaining 23 reviews, only single-zero
(zero events in only one arm of a two-arm study) pri-
mary studies were present, or it was either unclear or
not directly stated whether any double-zero studies were
included within the dataset.
Of these 64 reviews, 30 (46.9%) presented their outcome
as an odds ratio, 24 (37.5%) as a relative risk, and two as
a risk diﬀerence. In six included reviews, there was more
than one outcome with roughly equal importance in the
meta-analyses. In two reviews, the outcome, where sparse
data were incorporated, was an incidence rate.
Continuity corrections were used to circumvent prob-
lems with zero counts (in one or both arms of a study) that
result in diﬃculties with estimating ratio-based outcome
measures such as the odds ratio. Continuity corrections
are also required to calculate the variance (and hence con-
ﬁdence intervals) for a risk diﬀerence. However, it was
very diﬃcult to determine an accurate picture of how
continuity corrections were used.
Some included reviews clearly stated that continuity
corrections had been used (15/64, 23.4%). In 17/64 (26.6%)
included reviews, continuity corrections were not used.
In 32 cases it was not clearly stated whether continuity
corrections had been used or not.
The most popular primary continuity correction was
0.5, used in 14 of the 15 included reviews that stated their
continuity correction. Only one meta-analysis reference
used an alternative continuity correction with 0.25 being
the chosen value. Only one review performed a sensitivity
analysis across diﬀerent continuity corrections, using 0.5,
0.1 and 0.01, and reported that the continuity correction
did not alter the results. Three included reviews provided
a reason for their choice of continuity correction, and the
only reason cited was to minimise bias.
Several methods for incorporating single- and double-
zero studies into a meta-analysis that do not involve
continuity corrections were encountered in the included
reviews. The most frequently used was the Peto
method, employed by 12 studies. The use of a diﬀerence
metric rather than a ratio as the outcome measure
was used to circumvent problems with zeroes in seven
reviews, although calculation of conﬁdence intervals with
such methods would be problematic. Seven included
reviews resorted to the use of marginal analysis. Bayesian
methods were used to tackle sparsity of events in only two
included reviews.
Double-zero studies were included in analyses in 17 of
the 41 reviews where double-zero primary studies were
clearly present within the dataset. In two further reviews,
double-zero studies were included in a sensitivity analysis.
Double-zero studies were clearly excluded from analyses
in 18 reviews where they were present in the set of pri-
mary studies. Such an exclusion was either a deliberate
decision by the authors, shown by excluding the primary
study in forest plots of the meta-analysis, or was done by
default, the primary study being shown on a forest plot,
but being given a weighting of zero. The four remaining
included reviews were unclear as to whether or not these
double-zero primary studies were included.
Of the 19 included reviews where double-zero primary
studies were included in some way, seven made explicit
use of continuity corrections. In other included reviews
it was not clearly stated whether continuity corrections
had been used. Other options, such as using a marginal
analysis, were employed in some reviews, whilst in other
reviews the methodologies used were unclear.
Discussion
This paper has reviewed an extensive sample of pub-
lished meta-analyses where the primary outcome was an
adverse or unintended event. Reviews published in lan-
guages other than English were excluded, hence there is
a risk that methodologies used in reviews published in
other languages may diﬀer from those discussed here.
There was considerable variation in the methodology
employed across the sample, including designs of the pri-
mary studies incorporated in the meta-analyses, use of
ﬁxed or random eﬀect(s) measures, how to deal with
zero events in study arms, and how to assess study qual-
ity and publication bias. In many cases, the statistical
aspects were not clearly reported, with insuﬃcient detail
to discern the methods used. Often, little justiﬁcation
was given for the approaches to meta-analysis used. This
is perhaps, in part, due to the lack of speciﬁc guide-
lines available for meta-analysis of sparse/adverse events.
Not only would such guidelines improve the standard of
reporting of adverse event meta-analyses, they could also
circumvent disagreements in the literature due to the use
of alternative methods producing diﬀerent conclusions,
as was the case for the recent high-proﬁle concerns of
elevated cardiovascular risk in those taking rosiglitazone
[186-190].
Based on this review, one of the major areas of confu-
sion appears to be with regard to the use of continuity
corrections for dealing with sparse data for comparative
outcomes. Indeed the term continuity correction is pos-
sibly misleading, as these are in eﬀect nothing more than
arbitrary factors added to a cell count of zero. Where
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a study has zero events in both groups, we believe it
contains no information regarding the magnitude of the
odds ratio or relative risk, but adding a continuity correc-
tion to both sides (incorrectly) keeps it in the analysis for
methods which require it. Although not required for the
risk diﬀerence scale, and such a study does contain infor-
mation, a correction factor is required for the estimation
of associated variance which causes further confusion.
This latter point also raises the unanswered question of
whether the presence of double-zero studies should inﬂu-
ence the outcome metric. Bayesian methods present an
alternative way to deal with datasets including sparse data,
and Bayesian analyses are now easily implemented using
appropriate software. However, Bayesian methods were
used infrequently within the included reviews; with the
development of guidelines to support Bayesian analyses, it
may be that such methods would become more popular.
Many reviews in this sample included observational
studies, in some cases this was the only type of pri-
mary study included, whilst in other reviews both obser-
vational studies and trials were included. Observational
studies may oﬀer advantages over trials, such as a longer
period of follow-up. Inclusion of observational studies
also increases the number of studies and individuals
within ameta-analysis where both trials and observational
studies are available, thus increasing power. However, this
advantage may be counterbalanced by concerns regarding
bias in observational studies. The reviews included here
showed a variety of approaches to mixed study design; this
is an area where guidelines would assist in combining all
available data whilst addressing issues of diﬀerent study
design.
As mentioned in the introduction, a previous systematic
review of reviews and meta-analyses of primary studies of
adverse eﬀects of a drug intervention has been conducted
[4], including a total of 43 references, all published in 2006.
Of these, 15% assessed quality of primary studies, com-
pared to 42.2% of references in our review, and only 24
performed a meta-analysis. As seen in our review, there
was some poor reporting of the methods used for pool-
ing data, but 83% did report the method used for pooling
data and exploring heterogeneity. With regard to funding
source, 23% (of the 43 reviews) had pharmaceutical fund-
ing, compared to the 16.3% of references in our review that
had commercial funding. Hence, there is potentially some
suggestion of systematic diﬀerences between reviews con-
cerning only drugs and those including other interven-
tions, and between reviews that contain a meta-analysis
and those that do not (although such observations could
be confounded by the wider time range we considered).
Development of guidelines
Within the ﬁeld of meta-analysis for adverse events, the
concept of deﬁnitive guidelines is possibly too prescrip-
tive; the diverse nature of medical interventions, the
potential adverse outcomes and the ways they may be
measured, and the formats in which data may be available
preclude the use of standardised methods. However, gen-
eral guidelines for approaching speciﬁc methodological
issues (applying to other outcomes beyond adverse events)
may be more feasible and useful. We hope this review sets
the context in which future research and guidelines into
the conduct of adverse event meta-analyses can be placed.
There is perhaps a need for more research before
informed guidelines could be drafted. Many of the unique
issues relating to adverse event meta-analyses are due to
the typically sparse event data available for such analyses.
Such sparse data presents unique challenges, as high-
lighted by this review. As well as speciﬁc challenges, such
as dealing with zero events in arms of studies, there are
also potential concerns relating to the use of broadly
accepted meta-analysis methods in a sparse data context
due to the potentially very low power such methods may
have. For example, simulation has shown that tests for
heterogeneity have very low power in sparse data situa-
tions [191,192]. Similar issues are likely to exist for the
use of meta-regression, tests for publication bias [193] and
other methodologies. Rather than trying to use cutting-
edge advanced meta-analysis methodology, in a sparse
data context, it may often be wiser to restrict focus to
simpler methods (e.g. ﬁxed eﬀect models) and be real-
istic about the potentially limited conclusions that can
be drawn from the data. Since the primary aim of many
adverse eﬀect meta-analyses is to establish the existence
of an elevated risk of an event due to a particular inter-
vention, use of simple methods is, perhaps, consistent
with this aim. Information on the performance of diﬀer-
ent meta-analytic estimators for sparse data and the use
and avoidance of correction factors has been considered
at length elsewhere [191,192] and this is one domain in
which knowledge on which methods to use and which to
avoid is available.
Hierarchical models to address issues related to combi-
nation of diﬀerent study types have been developed [194],
and more recent developments on the use of methods to
adjust studies in meta-analysis to account for bias appear
to be promising [195,196]. However, further exploration
into the use of such methods in an adverse events context
is warranted.
Development of Bayesian methods is clearly an area
where further research would be both timely and ben-
eﬁcial, especially in the light of many of the diﬃcul-
ties surrounding meta-analysis of adverse events data,
which Bayesian methods may be able to address, such as
inclusion of primary studies with sparse events without
the need for continuity corrections using Markov Chain
Monte Carlo (MCMC) methods [197-200]. However, dif-
ﬁculties exist in ensuring that all prior distributions are
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plausibly vague, when not based on external information
– a challenge given how little data is sometimes available
[201,202].
Speciﬁcally to adverse events, an area where further
research would be valuable is the consideration of drug
class eﬀects, allowing information on multiple drugs of
the same class to be combined while acknowledging the
potential diﬀerences in eﬀects across drugs. This would
be an area where hierarchical (and potentially Bayesian)
models would be particularly useful [203]. Another clini-
cal aspect related to adverse events issues is that there may
be several indications for a certain intervention; patients
with diﬀerent conditions may be at varying risk of adverse
events, despite receiving the same intervention. Whilst it
is desirable to combine all available data to increase power,
any meta-analysis should be able to adjust for the diﬀer-
ences in indication for the intervention; as this scenario is
similar to combination of data regarding individual drugs
of the same class, hierarchical modelling may be a means
to achieve this.
Conclusion
Conducting meta-analyses where the outcome is an unin-
tended or adverse event presents a range of potential
diﬃculties, and requires careful consideration of the sta-
tistical issues, as well as an awareness of the clinical
context. This review has demonstrated that a diversity of
approaches have been employed when conducting such
meta-analyses. Hence, standardised guidelines may be
beneﬁcial in this area, even if, due to the range of clini-
cal situations and availability and format of data, they are
necessarily of a general nature. This is especially true since
a meta-analysis may present the only feasible method
to estimate potential risks, due to the often infrequent
occurrence of adverse events within an individual trial or
observational study.
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